1 / 15

Japanese AD Neuroimaging Initiative (J-ADNI) updates and new data July 10, 2010

Japanese AD Neuroimaging Initiative (J-ADNI) updates and new data July 10, 2010. Departments of Neuropathology, Graduate Schools of Medicine University of Tokyo Principal Investigator of J-ADNI Takeshi Iwatsubo. Japanese ADNI. Sapporo. 5-year study (since 2008) 38 clinical sites

elan
Download Presentation

Japanese AD Neuroimaging Initiative (J-ADNI) updates and new data July 10, 2010

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Japanese AD Neuroimaging Initiative (J-ADNI) updates and new dataJuly 10, 2010 Departments of Neuropathology, Graduate Schools of Medicine University of Tokyo Principal Investigator of J-ADNI Takeshi Iwatsubo

  2. Japanese ADNI Sapporo • 5-year study (since 2008) • 38 clinical sites • 600 subjects Hirosaki • 1.5T MRI • (3D MPRAGE, ADNI phantom) • PET • ---FDG ~70% • ---amyloid ~43% (PIB 10 sites, BF227 2 sites) • Blood + apoE (100%) • CSF ~39% • Clinical (14 compatible test batteries) Akita Iwate Tohoku Niigata Gumma, Tsukuba, Mihara Kanazawa ShinshuNCNPSaitama Kyorin Tokyo Met Geriatric Hosp Tokyo Med col, Nippon Med, Juntendo,TMDU, Tokyo Asahi/Chiba-higashi Tottori Kyoto Kyoto Pref Natl Longev., Hamamatsu, Kurihama, Yokohama Kobe, Osaka City Osaka, Nara Okayama Kagawa Fukuoka Kumamoto

  3. Mon, Jul 12, 1:20 - 1:30 PMFT-02-02 - Key Elements of Japanese ADNI and Moving Forward: What lessons can be learned for moving forward? Organization of J-ADNI Public Funding from NEDO and MHLW Advisor Ihara (Doshisha) Sawada (NEDO) Senda (Kobe, Biomed Res Innova) Ishii (Tokyo Met Inst Geront) Ito (Nagoya, Natl Inst Longevity) US-ADNI E/A-ADNI Matsuda (Saitama) PI Iwatsubo (U Tokyo) Weiner US-ADNI PI Asada Arai Sugishita Clinical core Imaging core groups MRI PI:Matsuda；PET: PI Ito PET QC: Senda, PIB: Ishii Kuwano (Arai) Biomarker core Tsukuba psychology Tohoku QC, evaluation of conversion Operation center Consortium office Imaging and clinical database（NCNP） feedback Sampling AD genome study Kuwano, Ihara Data registration QC, data analysis J-ADNI clinical sites （38 sites） Japanese-pharma Industry Scientific Advisory Board(11) Astellas, Eisai, Daiichi Sankyo Dainippon-Sumitomo, Shionogi Takeda, Tanabe-Mitsubishi Eli-Lilly, Merck-Banyu. BMS, Pfizer Yamashita Imaging company ISAB (7) GE, Siemens, Hitachi, Toshiba Shimadzu, Mediphysics, Micron

  4. Current status of J-ADNI recruitment (2010.7.8） total 393 (cerebrospinal fluid) FDG-PET MCI 172 NC 143 AD 78 Baseline visits by site Amyloid ＰＥＴ

  5. J-ADNIDemographics（2010. July） 25.6% （26.6%） 56.1% （53.5%） 60.6% （65.6%） Biomarker core PI RyozoKuwano Clinical core PI Takashi Asada, Hiroyuki Arai Total (n=377) Normal (n=137) MCI (n=162) AD (n=78) Age（USA） 71.1 67.9 (76.4) 72.8 (75.3) 73.1 (75.8) Sex（female）（USA） 56.5% 52.6% (48%) 55.6% (35.4%) 65.4% (47.4%) education（USA） 13.1 13.9 (15.6) 12.8 (16.0) 11.9 (14.7) % apoEe4(+) in 359 cases （USA）

  6. Exclusion (fail) upon screening Discontinuation (drop out): 18 /393 = ~4.6% / year Longitudinal follow-up baseline 6M 12M NL 40 56 47 MCI 83 61 28 (s/o conversion 16 cases) AD 34 29 15

  7. Optimal harmonization in major clinical batteries between US- and J-ADNI Neuropsychology PI MorihiroSugishita Mon, Jul 12, 11:30 AM – M. Sugishita P2-119 - Japanese versions equivalent to original English neuropsychological tests in ADNI

  8. Volumetric analysis by structural MRI MRI core PI Hiroshi Matsuda MRI/IT coreFumio Yamashita • Standardization beyond MRI equipment/vendor • Programs for correction and calibration Correction of signal equity Correction of distortion

  9. PET-QC core Rescan is necessary if Brain out of FOV, Too severe motion, Unqualified camera, Machine failure. Uploaded data: Images (FDG, PiB, BF227), Scan info. Order rescan Quick Query For FDG QC processing: Assess/correct for motion, Sum frames, Reorient with std voxel. Data cleaning: Check upon Data deficit, Protocol violation. Statistical images (3D-SSP) QC results Central Read Image Interpretation PET QCdatabase PETImage database PET QC PI M. Senda, 2010.7.10

  10. FDG-PETcentral read (baseline scan) March 12, 2010 cases AD pattern 11% (FTDpattern) (DLB etc) （ADpattern） 80% 70% 89% （normal pattern） 14% 6%

  11. Amyloid PET core PIKenji Ishii positive negative Positive 24% 75% 95% apoEe4 positive individuals are highly PIB positive from 60s Sun, Jul 11, 11:30 AM – P1-413 - The first results of amyloid imaging in Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) study

  12. Initial data on CSF Ab and tau quantitated by X-MAP technology in J-ADNI (R. Kuwano)

  13. Correlation of Ab(1-42) and total/p-tau in J-ADNI CSF Ab(1-42) Ab(1-42) Total tau P(T181)- tau Total tau Biomarker core PI RyozoKuwano P(T181)- tau

  14. Amyloid PET core PIKenji Ishii • PIB vs CSF A(1-42) in J-ADNI subjects Totaln= 45 (23 NC, 13 MCI, 9 AD) CSF Ab(1-42) pg/ml PIB Mean cortical SUVR Biomarker core PI RyozoKuwano

  15. World-wide ADNI symposium(Nov 22-23, 2009, Sendai) • 350 participants, 26 presentations from US-ADNI, J-ADNI, AIBL, E-ADNI, Korea, China • Presentations on WW-ADNI activities; discussions on WW-collaborations See you all again @ next WW-ADNI!

More Related